Skip to main content
. 2018 Jul 16;12(10):328–336. doi: 10.5489/cuaj.5378

Fig. 2.

Fig. 2

Pictographic description of variation in interprovincial access to life-prolonging therapies in metastatic castrate-resistant prostate cancer. ARAT: androgen receptor-axis-targeted therapies; Ra: radium.